Eczema usually starts in babies and young children (NHS, Atopic eczema). About 1 in 5 children in the UK develop it (British Association of Dermatologists, Atopic eczema), and NICE counts onset before the age of two among the pointers towards a diagnosis in a child. In babies aged 18 months or under the guideline expects dermatitis on the cheeks or the extensor surfaces rather than in the skin creases (NICE CG57, 1.1.1.2), so a rough, red patch on a four-month-old's face is the usual presentation rather than a strange one.
Parents of a baby with dry, itchy, inflamed skin arrive with three questions: whether this is normal, what to put on it, and when to ring someone. There is a fourth that comes before all of them, and it is the one with a large UK trial behind it. Daily emollient from birth was tested as a way of preventing eczema in the babies most likely to develop it. It did not work.
What the BEEP trial found about emollient from birth
BEEP was a multicentre, pragmatic, parallel-group randomised controlled trial run across 12 hospitals and four primary care sites in the UK. It enrolled 1394 term newborns, at least 37 weeks' gestation, at high risk of eczema, defined as having at least one first-degree relative with parent-reported eczema, allergic rhinitis or asthma diagnosed by a doctor. Of those, 693 were assigned to the emollient group and 701 to the control group. Families in the emollient group chose Doublebase Gel or Diprobase Cream and were advised to apply it at least once daily to the whole body, excluding the scalp (Chalmers et al, 2020).
The primary outcome was eczema at age 2 years, defined by UK Working Party criteria. It was present in 139 of 598 infants (23%) in the emollient group and 150 of 612 (25%) in the control group. The adjusted relative risk was 0.95, with a 95% confidence interval of 0.78 to 1.16 and p=0.61. The interval carries more information than the point estimate: it is tight enough to rule out the large protective effect the trial was built to detect, not merely too wide to call.
Poor adherence does not explain the result. At 12 months, 375 of 506 families, 74%, were still applying emollient satisfactorily.
The safety data ran the opposite way to the hope. Skin infections during the first year averaged 0.23 per child in the emollient group against 0.15 in the control group, an adjusted incidence rate ratio of 1.55 (95% CI 1.15 to 2.09). The authors' own summary is the line to carry away: "We found no evidence that daily emollient during the first year of life prevents eczema in high-risk children and some evidence to suggest an increased risk of skin infections" (Chalmers et al, 2020).
Prevention and treatment are two different questions
BEEP recruited newborns who did not have eczema and asked whether moisturising them daily would stop it appearing. That is a different question from what to do for a baby who has eczema now, and the trial does not answer it. For eczema that is already present, NICE is unambiguous: emollients are the basis of management and should always be used, with other treatment stepped up or down around them according to severity (NICE CG57, 1.5.1.1). Nothing in the BEEP result is a reason to stop moisturising a baby who has eczema.
What emollient is doing once eczema is there
Eczema-prone skin leaks water outward and lets irritants and microorganisms inward, the sequence set out in what the skin barrier is. Emollient replaces part of the missing lipid and holds water in the outer layer, which is why the guideline treats it as the base everything else sits on rather than an optional extra.
The quantities NICE expects surprise most parents. Prescribers are asked to offer a choice of unperfumed emollients for daily use and to prescribe large quantities, 250 g to 500 g weekly (NICE CG57, 1.5.1.4). Children should use emollients in larger amounts and more often than other treatments, over the whole body, and keep using them alongside every other treatment (1.5.1.5). NHS advice for atopic eczema is to apply emollients "as often as possible (at least 2 times a day)".
Washing is part of the same job. The guideline asks for leave-on emollients or emollient soap substitutes instead of soaps and detergent-based wash products (1.5.1.10). In a baby's routine that means the bubble bath and the baby wash, not only the family soap.
Steroid creams on a baby, and what the guideline says
This is where a parent most wants a rule, and the guideline supplies several. Potency is matched to severity and to site: mild for mild eczema, moderate for moderate, potent for severe, mild potency for the face and neck except short-term use of moderate potency for severe flares over 3 to 5 days, and moderate or potent preparations for short periods only, 7 to 14 days, in vulnerable sites such as the armpits and groin (NICE CG57, 1.5.1.13). Topical corticosteroids are prescribed for application only once or twice daily (1.5.1.14). Very potent preparations are not used in children without specialist dermatological advice (1.5.1.13), and potent topical corticosteroids are not used in children aged under 12 months without specialist dermatological supervision (1.5.1.17).
Two things the guideline steers away from are worth knowing, because both get suggested at baby groups. Oral antihistamines are not routinely used to manage atopic eczema in children (1.5.1.33). Whole-body occlusive dressings, including wet wrap therapy, and whole-body dry bandages are not a first-line treatment (1.5.1.31).
What your baby is prescribed, at what potency and for how long, is a decision for the GP, health visitor or dermatology team who can see the skin. The paragraphs above describe the guidance those people work from. They are not an instruction to start, stop or change anything your baby has been given.
When to ring someone
The NHS names the signs that warrant an urgent GP appointment or a call to NHS 111: eczema that is "blistered, crusty, leaking fluid or has spots filled with pus", eczema that is "painful, swollen or feels warm", eczema that "suddenly gets worse or gets bigger", and a high temperature or feeling generally unwell alongside it (NHS, Atopic eczema).
NICE separates those into two patterns. Bacterial infection shows as weeping, pustules, crusts, rapidly worsening eczema or eczema failing to respond to therapy, with fever and malaise (CG57, 1.5.1.36). Eczema herpeticum, herpes simplex spreading through skin whose barrier is already broken, shows as areas of rapidly worsening, painful eczema, clustered blisters that look like early-stage cold sores, and punched-out erosions (1.5.1.42). Severe eczema that has not responded to optimal topical therapy after one week is an urgent referral rather than a wait-and-see (1.7.1.2). How fast each threshold moves, and which one is same-day, is set out in when to see a dermatologist.
Triggers worth checking, and the food question
NICE asks clinicians to look for trigger factors in a specific list: irritants such as soaps and detergents, including shampoos, bubble baths, shower gels and washing-up liquids, then skin infections, contact allergens, food allergens and inhalant allergens (CG57, 1.4.1.1). In a first-year routine most of the irritant column is within reach: the wash products, what the babygrows are washed in, the temperature of the bath, and how warm the room is overnight.
Food sits on that list too, and it is the question parents ask soonest. It has its own criteria for when allergy is suspected at all, and its own route through a clinician rather than through the kitchen, all of which is in baby eczema and food allergy.
Facial skin is the other thing that behaves differently in the first year. Cheeks and chin take the friction of feeding, dribble and sleeping face down, and thinner facial skin absorbs whatever is applied to it more readily than the limbs do, which is why the facial routine has separate rules from the rest of the body.
Will they still have this later
Nobody can answer that at six months. The NHS says the symptoms tend to get better as children get older, which describes a population pattern rather than a promise about one child, and the cohort evidence underneath it is less tidy than the reassurance sounds. What the largest analyses actually found, including where they disagree with each other, is in can eczema be cured, or only managed.
In the meantime the work is unglamorous and largely the same every day: emollient in quantity, a wash routine that does not strip the skin, topical steroid used as prescribed when a flare needs it, and a low threshold for showing an infected-looking patch to someone who can examine it.
References
- Chalmers JR, Haines RH, Bradshaw LE, et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. The Lancet, 2020, 395:962-972. https://doi.org/10.1016/S0140-6736(19)32984-8 (free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC7086156/)
- National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management (CG57), 2025. https://www.ncbi.nlm.nih.gov/books/NBK571009/
- NHS. Atopic eczema. https://www.nhs.uk/conditions/atopic-eczema/
- British Association of Dermatologists. Atopic eczema, patient information leaflet. https://www.bad.org.uk/pils/atopic-eczema/